These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 22304839)

  • 1. A review of the role of apolipoprotein C-II in lipoprotein metabolism and cardiovascular disease.
    Kei AA; Filippatos TD; Tsimihodimos V; Elisaf MS
    Metabolism; 2012 Jul; 61(7):906-21. PubMed ID: 22304839
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human apolipoprotein A-II determines plasma triglycerides by regulating lipoprotein lipase activity and high-density lipoprotein proteome.
    Julve J; Escolà-Gil JC; Rotllan N; Fiévet C; Vallez E; de la Torre C; Ribas V; Sloan JH; Blanco-Vaca F
    Arterioscler Thromb Vasc Biol; 2010 Feb; 30(2):232-8. PubMed ID: 19910634
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insights into apolipoprotein C metabolism from transgenic and gene-targeted mice.
    Jong MC; Havekes LM
    Int J Tissue React; 2000; 22(2-3):59-66. PubMed ID: 10937355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein distribution of apolipoprotein C-III and its relationship to the presence in plasma of triglyceride-rich remnant lipoproteins.
    Marcoux C; Tremblay M; Fredenrich A; Davignon J; Cohn JS
    Metabolism; 2001 Jan; 50(1):112-9. PubMed ID: 11172484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apolipoprotein C-II: New findings related to genetics, biochemistry, and role in triglyceride metabolism.
    Wolska A; Dunbar RL; Freeman LA; Ueda M; Amar MJ; Sviridov DO; Remaley AT
    Atherosclerosis; 2017 Dec; 267():49-60. PubMed ID: 29100061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apolipoprotein C-III: understanding an emerging cardiovascular risk factor.
    Ooi EM; Barrett PH; Chan DC; Watts GF
    Clin Sci (Lond); 2008 May; 114(10):611-24. PubMed ID: 18399797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ABC of apolipoprotein C-III: a clinically useful new cardiovascular risk factor?
    Chan DC; Chen MM; Ooi EM; Watts GF
    Int J Clin Pract; 2008 May; 62(5):799-809. PubMed ID: 18201179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide.
    Sakurai T; Sakurai A; Vaisman BL; Amar MJ; Liu C; Gordon SM; Drake SK; Pryor M; Sampson ML; Yang L; Freeman LA; Remaley AT
    J Pharmacol Exp Ther; 2016 Feb; 356(2):341-53. PubMed ID: 26574515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach.
    Reimund M; Wolska A; Risti R; Wilson S; Sviridov D; Remaley AT; Lookene A
    Biochem Biophys Res Commun; 2019 Oct; 519(1):67-72. PubMed ID: 31477272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human intestinal lipoproteins. Studies in chyluric subjects.
    Green PH; Glickman RM; Saudek CD; Blum CB; Tall AR
    J Clin Invest; 1979 Jul; 64(1):233-42. PubMed ID: 221544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endothelial-derived lipoprotein lipase is bound to postprandial triglyceride-rich lipoproteins and mediates their hepatic clearance in vivo.
    Heeren J; Niemeier A; Merkel M; Beisiegel U
    J Mol Med (Berl); 2002 Sep; 80(9):576-84. PubMed ID: 12226739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inverse association between apolipoprotein C-II and cardiovascular mortality: role of lipoprotein lipase activity modulation.
    Silbernagel G; Chen YQ; Rief M; Kleber ME; Hoffmann MM; Stojakovic T; Stang A; Sarzynski MA; Bouchard C; März W; Qian YW; Scharnagl H; Konrad RJ
    Eur Heart J; 2023 Jul; 44(25):2335-2345. PubMed ID: 37155355
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Pressure-dependent Model for the Regulation of Lipoprotein Lipase by Apolipoprotein C-II.
    Meyers NL; Larsson M; Olivecrona G; Small DM
    J Biol Chem; 2015 Jul; 290(29):18029-18044. PubMed ID: 26026161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lipid and lipoprotein metabolism in chronic kidney disease.
    Kaysen GA
    J Ren Nutr; 2009 Jan; 19(1):73-7. PubMed ID: 19121776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Apolipoprotein C-III: a potent modulator of hypertriglyceridemia and cardiovascular disease.
    Kohan AB
    Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):119-25. PubMed ID: 25692924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences.
    Vaziri ND
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F262-72. PubMed ID: 16403839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Apolipoprotein C-II deficiency syndrome. Clinical features, lipoprotein characterization, lipase activity, and correction of hypertriglyceridemia after apolipoprotein C-II administration in two affected patients.
    Baggio G; Manzato E; Gabelli C; Fellin R; Martini S; Enzi GB; Verlato F; Baiocchi MR; Sprecher DL; Kashyap ML
    J Clin Invest; 1986 Feb; 77(2):520-7. PubMed ID: 3944267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aromatic residues in the C terminus of apolipoprotein C-III mediate lipid binding and LPL inhibition.
    Meyers NL; Larsson M; Vorrsjö E; Olivecrona G; Small DM
    J Lipid Res; 2017 May; 58(5):840-852. PubMed ID: 28159869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apolipoprotein C-II and C-III preferably transfer to both high-density lipoprotein (HDL)2 and the larger HDL3 from very low-density lipoprotein (VLDL).
    Yamazaki A; Ohkawa R; Yamagata Y; Horiuchi Y; Lai SJ; Kameda T; Ichimura N; Tohda S; Tozuka M
    Biol Chem; 2021 May; 402(4):439-449. PubMed ID: 33934596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.